Skip to main content

# multiomics approaches

2 related articles

Subscribe to updates

World Journal of Methodology Sep 20, 2026
Precision Management of Gastrointestinal Tumor-Associated Osteoporosis Driven by Cutting-Edge Technologies: Current Status, Challenges, and Future Prospects
This review systematically evaluates the methodological quality, clinical validity, and translational evidence of cutting-edge technologies in the precision management of gastrointestinal tumor-associated osteoporosis (GTO), summarizing their current applications in AI-assisted early screening and risk prediction, nano-enabled targeted bone protection, and multiomics-based exploration of the tumor-bone-gut axis, and discussing barriers to clinical translation such as limited AI generalizability, nanomedicine safety and manufacturing challenges, difficulties in multidimensional data integration and standardization, imperfect multidisciplinary collaboration, and ethical concerns, concluding that these technologies are expected to move GTO management from empirical practice toward precision m
This review systematically evaluates the methodological quality, clinical validity, and translational evidence of cutting-edge technologies in the precision management of gastrointestinal tumor-associated osteoporosis (GTO), summarizing their current applications in AI-assisted early screening and risk prediction, nano-enabled targeted bone protection, and multiomics-based exploration of the tumor-bone-gut axis, and discussing barriers to clinical translation such as limited AI generalizability, nanomedicine safety and manufacturing challenges, difficulties in multidimensional data integration and standardization, imperfect multidisciplinary collaboration, and ethical concerns, concluding that these technologies are expected to move GTO management from empirical practice toward precision m
Fifth Affiliated Hospital of Zhengzhou University Henan Provincial People's Hospital Zhengzhou People's Hospital Zhengzhou University
Peng Wang（First author）
gastrointestinal tumor-associated osteoporosis Precision medicine AI-assisted early screening and risk prediction nanotargeted drug delivery systems multiomics approaches
Chinese Medical Journal Sep 15, 2026
Non-invasive tests for early-stage liver fibrosis: current advances and challenges
This review systematically evaluates established and emerging non-invasive tests for detecting early-stage liver fibrosis (F1–F2), spanning serum biomarkers, molecular imaging probes, AI-based analysis of conventional imaging, alternative biofluids such as urine, exhaled breath and saliva, gut microbiota-derived biomarkers, and multiomics-integrated models, concluding that these approaches show diagnostic promise but remain constrained by limited validation, absent standardization, and unclear integration into clinical pathways, and proposing a tiered diagnostic framework as a near-term implementation route.
This review systematically evaluates established and emerging non-invasive tests for detecting early-stage liver fibrosis (F1–F2), spanning serum biomarkers, molecular imaging probes, AI-based analysis of conventional imaging, alternative biofluids such as urine, exhaled breath and saliva, gut microbiota-derived biomarkers, and multiomics-integrated models, concluding that these approaches show diagnostic promise but remain constrained by limited validation, absent standardization, and unclear integration into clinical pathways, and proposing a tiered diagnostic framework as a near-term implementation route.
National Clinical Research Center for Digestive Diseases Capital Medical University Beijing Friendship Hospital
Caihong Wang（First author）
Non-invasive tests for early-stage liver fibrosis Liver fibrosis multiomics approaches

You’re all caught up